The Use of Metyrosine in the Treatment of Pheochromocytoma and Paraganglioma Patients: A Review of the Literature

Metyrosine (α-methyl-parathyrosine) functions as an inhibitor of tyrosine hydroxylase, thereby impeding the conversion of tyrosine to 3,4-dihydroxyphenylalanine. This reaction represents the rate-limiting step in the synthesis of catecholamines. This review examines the mechanisms of metyrosine acti...

詳細記述

書誌詳細
出版年:Archives of Basic and Clinical Research
主要な著者: Mansura Babayeva, Osman Kağan Çakır, Gülbaniz Hüseynova, Halis Süleyman
フォーマット: 論文
言語:英語
出版事項: Erzincan Binali Yıldırım University School of Medicine 2025-05-01
主題:
オンライン・アクセス:https://abcresearch.net/articles/the-use-of-metyrosine-in-the-treatment-of-pheochromocytoma-and-paraganglioma-patients-a-review-of-the-literature/doi/ABCR.2025.24317
その他の書誌記述
要約:Metyrosine (α-methyl-parathyrosine) functions as an inhibitor of tyrosine hydroxylase, thereby impeding the conversion of tyrosine to 3,4-dihydroxyphenylalanine. This reaction represents the rate-limiting step in the synthesis of catecholamines. This review examines the mechanisms of metyrosine action and its application for treatment purposes. The published literature was collated from a range of scientific databases, including PubMed, SciFinder, ScienceDirect, Wiley Online Library, Google Scholar and Web of Science. The use of metyrosine has been demonstrated to reduce catecholamine biosynthesis in patients with catecholamine-secreting pheochromocytoma and paraganglioma. The safety and efficacy of metyrosine in the treatment of pheochromocytoma and paraganglioma is substantiated by empirical evidence from studies demonstrating its general tolerability and clinical practice use. Metyrosine has been shown to potentially mitigate the occurrence of surgical complications by enhancing intraoperative hemodynamics. Studies have demonstrated that the administration of metyrosine prior to pheochromocytoma and paraganglioma surgery reduces the risk of hypertensive crisis and severe hypertension, as well as intraoperative haemodynamic variability. It is imperative that further research is conducted to elucidate the pharmacokinetics, intricate molecular mechanisms, and safety profile of methyrone. To this end, the utilization of meticulously designed randomized clinical trials is crucial.
ISSN:2687-4520
2687-4482